Protagonist Logo. Click to navigate to a home page

HEPCIDIN MIMETIC: RUSFERTIDE (PTG-300) & ORAL IL-23R ANTAGONIST (PN-235, JNJ-77242113)

PROGRAMS CANDIDATES STUDY PHASE 1 PHASE 2 PHASE 3 KEY MILESTONES
HEMATOLOGY & BLOOD DISORDERS
Rusfertide
(PTG-300)
Hepcidin
Mimetic

Takeda Logo		 Rusfertide
(PTG-300)		 VERIFY
PV Ph3, n~250
 • Primary endpoint top-line results in Q1 ‘25
REVIVE
PV Ph2, n=70, 40 wk study +3yr OLE
 • Completed; OLE ongoing
THRIVE
PV LTE
 • For REVIVE patients on years 3-5
PACIFIC
PV Ph2 Elevated HcT (>48%), n=20
• Completed
INFLAMMATORY & IMMUNOMODULATORY DISEASES
Oral IL-23R
Antagonist
(Partnered)
Janssen Logo		 JNJ-2113
(PN-235) 		FRONTIER 1 & 2
Psoriasis Ph2b, n~255
• Completed
ICONIC-LEAD
Psoriasis Ph3, n~600
• Enrollment completed; 16-week 1°EP Q4
ICONIC-TOTAL
Psoriasis Ph3, n~300
• Enrollment completed; 16-week 1°EP Q4
ICONIC-ADVANCE
Psoriasis 1 Ph 3, n~750
• JNJ-2113 vs. deucravacitinib; completion ~ Mar ‘25 3
ICONIC-ADVANCE
Psoriasis 2 Ph 3, n~675
• JNJ-2113 vs. deucravacitinib; completion ~ Apr ‘25 4
Pustular/Erythrodermic
Psoriasis Ph 3, n~16
• Primary completion ~ Feb ‘25 5
ULCERATIVE COLITIS (UC)
ANTHEM Ph2b, n~240
 • Primary Completion ~ May ’25 6
DISCOVERY
Discovery
Oral IL-17
• Oral peptide development candidate by EOY 7
HEME
• Leads in heme program
Metabolic

1 See clinicaltrials.gov NCT06095115

2 See clinicaltrials.gov NCT06095102
3 See clinicaltrials.gov NCT06143878

4 See clinicaltrials.gov NCT06220604

5 See clinicaltrials.gov NCT06295692

6 See clinicaltrials.gov NCT06049017

7 Development Candidate: ready for IND enabling studies

Share by:
×

Health Equity: Improving Access to Medicines, Ensuring Diverse Representation

Spotlight, Arturo Molina, MD, Chief Medical Officer

Dr. Molina, how are you helping to advance access to medicines?

At Protagonist, we work hard to meet the needs of the patient communities who are relying on us to innovate new and better medicines. Part of our commitment to them includes working to advance our medicines through clinical studies as quickly as possible and ensuring patients can access investigational therapies outside of our clinical trials, which has allowed some patients in critical need to access our therapies for several additional years after trials conclude.

We’re seeing a greater push for better representation in therapeutic innovation across the industry. How is Protagonist supporting diverse and equitable discovery and development?

Protagonist actively works to ensure we have strong patient representation in our clinical studies. We actively seek patients from across urban, suburban, and rural locations, from varying age groups and from among diverse backgrounds to ensure equitable patient representation in our study data.

We’re particularly concerned aging populations are left out of clinical studies, and we’re currently working to recruit older patients into our trials.